|Articles|April 15, 2002

Excludes most of Asia: Tacrolimus licensing deal links Sucampo, Fujisawa

Bethesda, MD-Sucampo Pharmaceuticals Inc. has won the exclusive right to license Fujisawa's tacrolimus for ophthalmic use in the United States, Europe, and much of the world.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Latest CME